This study is testing a new drug called fianlimab along with another drug cemiplimab in adults with a serious skin cancer called melanoma. The study compares these drugs to an existing drug called pembrolizumab. All these drugs are known as immune checkpoint inhibitors, which help the immune system fight cancer. The study aims to see if the combination of fianlimab and cemiplimab works better than pembrolizumab alone.

The study also looks at what side effects might happen, how much of the study drugs are in the blood, and if the body makes antibodies (proteins that fight infections) against the drugs. This could affect how well the drugs work and could cause side effects. Additionally, the study observes if these drugs improve life quality.

• The study is for people with certain stages of melanoma, who are fit for surgery.
• Participants must undergo several health checks, including scans, before joining.
• The study excludes people with certain health conditions or recent treatments.

Check if you meet the criteria and consider the potential benefits and risks before participating.